Characterization of Cysteine-Linked Conjugation Profiles of Immunoglobulin G1 and Immunoglobulin G2 Antibody-Drug Conjugates

Journal of Pharmaceutical Sciences

Volumn 104, Issue 4, 2015, Pages 1362-1372

  Wiggins, Brian ^a   Liu Shin, Lily ^a   Yamaguchi, Hideto ^b   Ratnaswamy, Gayathri ^a  

^a Agensys Inc   (United States)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

biopharmaceuticals characterization; calorimetry (DSC); conjugation; HPLC (high performance pressure liquid chromatography); IgG antibody; mass spectrometry; monoclonal antibody; protein structure

Indexed keywords

ANTIBODY CONJUGATE; CYSTEINE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; UNCLASSIFIED DRUG; VEDOTIN; CAC10-VCMMAE; CROSS LINKING REAGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MAYTANSINE; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; TRASTUZUMAB EMTANSINE;

ARTICLE; CAPILLARY ELECTROPHORESIS; DIFFERENTIAL SCANNING CALORIMETRY; DISULFIDE BOND; DRUG CONJUGATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; HYDROPHOBICITY; ISOMER; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PEPTIDE MAPPING; REVERSED PHASE LIQUID CHROMATOGRAPHY; THERMOSTABILITY; TRANSITION TEMPERATURE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; CHEMICAL PHENOMENA; CHEMISTRY; DRUG STABILITY; MEDICINAL CHEMISTRY; PHARMACEUTICS; PROCEDURES; PROTEIN STABILITY; TEMPERATURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; CROSS-LINKING REAGENTS; CYSTEINE; DRUG STABILITY; ELECTROPHORESIS, CAPILLARY; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MASS SPECTROMETRY; MAYTANSINE; OLIGOPEPTIDES; PEPTIDE MAPPING; PROTEIN STABILITY; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 84924770352     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24338     Document Type: Article

References (27)

1. Flygare JA, Pillow TH, Aristoff P. 2013. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 81(1):113-121.
2. Roberts SA, Andrews PA, Blanset D, Flagella KM, Gorovits B, Lynch CM, Martin PL, Kramer-Stickland K, Thibault S, Warner G. 2013. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology. Regul Toxicol Pharmacol 67(3):382-391.
3. Alley SC, Okeley NM, Senter PD. 2010. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 14(4):529-537.
4. Sun MMC, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FGM, Ihle NC, Senter PD, Alley SC. 2005. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16(5):1282-1290.
5. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD. 2003. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21(7):778-784.
6. Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, Fodor S, Kelner DN, Flynn GC, Liu YD, Bondarenko PV, Ricci MS, Dillon TM, Balland A. 2008. Human IgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem 283(23) :16194-16205.
7. Liu YD, Wang T, Chou R, Chen L, Kannan G, Stevenson R, Goetze AM, Jiang XG, Huang G, Dillon TM, Flynn GC. 2013. IgG2 disulfide isoform conversion kinetics. Mol Immunol 54(2):217-226.
8. Li X, Wang F, Xu W, May K, Richardson D, Liu H. 2013. Disulfide bond assignment of an IgG1 monoclonal antibody by LC-MS with post-column partial reduction. Anal Biochem 436(2):93-100.
9. Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, Plant M, Henkle B, Li Y, Deechongkit S, Varnum B, Wypych J, Balland A, Bondarenko PV. 2008. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 283(23):16206-16215.
10. Liu H, May K. 2012. Disulfide bond structures of IgG molecules: Structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 4(1):17-23.
11. Wang Y, Lu Q, Wu S-L, Karger BL, Hancock WS. 2011. Characterization and comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies: Using LC-MS with electron transfer dissociation. Anal Chem 83(8):3133-3140.
12. Wang X, Kumar S, Singh S. 2011. Disulfide scrambling in IgG2 monoclonal antibodies: Insights from molecular dynamics simulations. Pharm Res 28(12):3128-3144.
13. Liu H, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. 2010. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal Chem 82(12):5219-5226.
14. Montano RF, Morrison SL. 2002. Influence of the isotype of the light chain on the properties of IgG. J Immunol 168(1):224-231.
15. Shen Y, Zeng L, Zhu A, Blanc T, Patel D, Pennello A, Bari A, Ng S, Persaud K, Kang YK, Balderes P, Surguladze D, Hindi S, Zhou Q, Ludwig DL, Snavely M. 2013. Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity. MAbs 5(3):418-431.
16. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, Solis WA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A, Wong WL, Vandlen R, Kaur S, Sliwkowski MX, Scheller RH, Polakis P, Junutula JR. 2012. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30(2):184-189.
17. Adem YT, Schwarz KA, Duenas E, Patapoff TW, Galush WJ, Esue O. 2014. Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconjug Chem 25(4):656-664.
18. Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE. 2014. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. AAPS J 16:994-1008.
19. Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA. 2004. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063-7070.
20. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, Gill H, Shen BQ, Rubinfeld B, Tibbitts J, Kaur S, Theil FP, Fielder PJ, Khawli LA, Lin K. 2011. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 22(10):1994-2004.
21. McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, Andreyka J, Stone I, Hamblett KJ, Francisco JA, Carter P. 2006. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 19(7):299-307.
22. Le LN, Moore JM, Ouyang J, Chen X, Nguyen MD, Galush WJ. 2012. Profiling antibody drug conjugate positional isomers: A system-of-equations approach. Anal Chem 84(17):7479-7486.
23. Beckley NS, Lazzareschi KP, Chih HW, Sharma VK, Flores HL. 2013. Investigation into temperature-induced aggregation of an antibody drug conjugate. Bioconjug Chem 24(10):1674-1683.
24. Pan LY, Salas-Solano O, Valliere-Douglass JF. 2014. Conformation and dynamics of interchain cysteine-linked antibody-drug conjugates as revealed by hydrogen/deuterium exchange mass spectrometry. Anal Chem 86(5):2657-2664.
25. Zhang Q, Flynn GC. 2013. Cysteine racemization on IgG heavy and light chains. J Biol Chem 288(48):34325-34335.
26. Ouellette D, Alessandri L, Piparia R, Aikhoje A, Chin A, Radziejewski C, Correia I. 2009. Elevated cleavage of human immunoglobulin gamma molecules containing a lambda light chain mediated by iron and histidine. Anal Biochem 389(2):107-117.
27. Hutterer KM, Hong RW, Lull J, Zhao X, Wang T, Pei R, Le ME, Borisov O, Piper R, Liu YD, Petty K, Apostol I, Flynn GC. 2013. Monoclonal antibody disulfide reduction during manufacturing: Untangling process effects from product effects. MAbs 5(4):608-613.